Cellectar Biosciences, Inc.

NasdaqCM:CLRB Stock Report

Market Cap: US$10.5m

Cellectar Biosciences Management

Management criteria checks 2/4

Cellectar Biosciences' CEO is Jim Caruso, appointed in Jun 2015, has a tenure of 9.5 years. total yearly compensation is $1.97M, comprised of 30.5% salary and 69.5% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $12.48K. The average tenure of the management team and the board of directors is 2.8 years and 8.6 years respectively.

Key information

Jim Caruso

Chief executive officer

US$2.0m

Total compensation

CEO salary percentage30.5%
CEO tenure9.5yrs
CEO ownership0.1%
Management average tenure2.8yrs
Board average tenure8.6yrs

Recent management updates

Recent updates

We Think Cellectar Biosciences (NASDAQ:CLRB) Needs To Drive Business Growth Carefully

Aug 08
We Think Cellectar Biosciences (NASDAQ:CLRB) Needs To Drive Business Growth Carefully

Cellectar Biosciences: A Shoestring Opportunity You're About To Miss

Feb 12

Here's Why We're Watching Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation

Aug 23
Here's Why We're Watching Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation

Cellectar Biosciences GAAP EPS of -$1.22 misses by $0.19

Aug 05

Cellectar announces reverse stock split

Jul 21

We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate

May 10
We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate

Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Invest In Growth?

Jan 20
Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Invest In Growth?

Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Deliver On Growth Plans?

Oct 05
Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Deliver On Growth Plans?

Cellectar shares fall after mid-stage CLR 131 trial data fails to impress

Jun 04

We're Hopeful That Cellectar Biosciences (NASDAQ:CLRB) Will Use Its Cash Wisely

May 20
We're Hopeful That Cellectar Biosciences (NASDAQ:CLRB) Will Use Its Cash Wisely

Cellectar Biosciences EPS beats by $0.03

May 10

Cellectar gets notification of formal grant from Australian and Mexican patent authorities

Apr 27

Cellectar commences pivotal trial of CLR 131 in a rare form bone marrow cancer

Jan 12

Cellectar Bio readies stock offering

Dec 23

We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate

Nov 30
We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate

Cellectar Biosciences EPS beats by $0.05

Nov 09

Cellectar Bio's lead asset shows encouraging action in early-stage study of pediatric tumors

Nov 05

CEO Compensation Analysis

How has Jim Caruso's remuneration changed compared to Cellectar Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$50m

Jun 30 2024n/an/a

-US$53m

Mar 31 2024n/an/a

-US$62m

Dec 31 2023US$2mUS$600k

-US$43m

Sep 30 2023n/an/a

-US$45m

Jun 30 2023n/an/a

-US$36m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$1mUS$569k

-US$32m

Sep 30 2022n/an/a

-US$27m

Jun 30 2022n/an/a

-US$25m

Mar 31 2022n/an/a

-US$24m

Dec 31 2021US$2mUS$523k

-US$24m

Sep 30 2021n/an/a

-US$22m

Jun 30 2021n/an/a

-US$20m

Mar 31 2021n/an/a

-US$17m

Dec 31 2020US$1mUS$475k

-US$15m

Sep 30 2020n/an/a

-US$15m

Jun 30 2020n/an/a

-US$15m

Mar 31 2020n/an/a

-US$14m

Dec 31 2019US$934kUS$451k

-US$14m

Sep 30 2019n/an/a

-US$15m

Jun 30 2019n/an/a

-US$16m

Mar 31 2019n/an/a

-US$16m

Dec 31 2018US$770kUS$425k

-US$15m

Sep 30 2018n/an/a

-US$17m

Jun 30 2018n/an/a

-US$15m

Mar 31 2018n/an/a

-US$16m

Dec 31 2017US$994kUS$410k

-US$15m

Compensation vs Market: Jim's total compensation ($USD1.97M) is above average for companies of similar size in the US market ($USD651.40K).

Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.

CEO

Jim Caruso (65 yo)

9.5yrs

Tenure

US$1,965,140

Compensation

Mr. James V. Caruso, also known as Jim, is Member of Advisory Board & Director of Hip Innovation Technology, LLC. Mr. Caruso has been the Chief Executive Officer and President of Cellectar Biosciences, Inc...

Leadership Team

NamePositionTenureCompensationOwnership
James Caruso
President9.5yrsUS$1.97m0.12%
$ 12.5k
Chad Kolean
VP, CFO & Secretary2.8yrsUS$1.11m0.10%
$ 10.8k
Jarrod Longcor
Chief Operating Officer2.8yrsUS$1.36m0.13%
$ 13.5k
Darrell Lea
Chief Commercial Officer2.1yrsno data0.096%
$ 10.0k
Andrei Shustov
Senior Vice President of Medical1.8yrsno data0.13%
$ 14.0k

2.8yrs

Average Tenure

52yo

Average Age

Experienced Management: CLRB's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
James Caruso
President9.5yrsUS$1.97m0.12%
$ 12.5k
John Neis
Independent Director16.8yrsUS$93.25k0.015%
$ 1.6k
Frederick Driscoll
Independent Director7.7yrsUS$93.25k0.0047%
$ 491.7
Stefan Loren
Independent Director9.5yrsUS$93.25k0%
$ 0
Douglas Swirsky
Independent Chairman of the Board7.7yrsUS$109.88k0.0061%
$ 634.0
Asher Chanan-Khan
Independent Director3.5yrsUS$48.25k0%
$ 0

8.6yrs

Average Tenure

62.5yo

Average Age

Experienced Board: CLRB's board of directors are considered experienced (8.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 02:22
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cellectar Biosciences, Inc. is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kumaraguru RajaBrookline Capital Markets
Keith MarkeyGriffin Securities
Swayampakula RamakanthH.C. Wainwright & Co.